TRAF2 Suppresses Basal IKK Activity in Resting Cells and TNFα Can Activate IKK in TRAF2 and TRAF5 Double Knockout Cells

Journal of Molecular Biology

Volumn 389, Issue 3, 2009, Pages 495-510

  Zhang, Laiqun ^a   Blackwell, Ken ^a   Thomas, Gregory S ^a   Sun, Shujie ^a   Yeh, Wen Chen ^b   Habelhah, Hasem ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

apoptosis; NF B; TNF ; TRAF2; TRAF5

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 8; CYCLOOXYGENASE 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B ALPHA; I KAPPA B KINASE; I KAPPA B KINASE BETA; INHIBITOR OF APOPTOSIS PROTEIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN P100; PROTEIN P52; RANTES; RECEPTOR INTERACTING PROTEIN 140; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5;

ANIMAL CELL; APOPTOSIS; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME REPRESSION; GENE EXPRESSION; GENE TARGETING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UBIQUITINATION; WILD TYPE;

EID: 65649150701     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.04.054     Document Type: Article

References (35)

1. Bradley J.R., and Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20 (2001) 6482-6491
2. Wajant H., Henkler F., and Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell. Signalling 13 (2001) 389-400
3. Varfolomeev E.E., and Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie?. Cell 116 (2004) 491-497
4. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11 (2001) 372-377
5. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004) 280-288
6. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7 (2005) 758-765
7. Wu C.J., Conze D.B., Li T., Srinivasula S.M., and Ashwell J.D. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat. Cell Biol. 8 (2006) 398-406
8. Ea C.K., Deng L., Xia Z.P., Pineda G., and Chen Z.J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22 (2006) 245-257
9. Habelhah H., Takahashi S., Cho S.G., Kadoya T., Watanabe T., and Ronai Z. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J. 23 (2004) 322-332
10. Yamamoto M., Okamoto T., Takeda K., Sato S., Sanjo H., Uematsu S., et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat. Immunol. 7 (2006) 962-970
11. Yeh W.C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A., et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7 (1997) 715-725
12. Nguyen L.T., Duncan G.S., Mirtsos C., Ng M., Speiser D.E., Shahinian A., et al. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity 11 (1999) 379-389
13. Grech A.P., Amesbury M., Chan T., Gardam S., Basten A., and Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 21 (2004) 629-642
14. Tada K., Okazaki T., Sakon S., Kobarai T., Kurosawa K., Yamaoka S., et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J. Biol. Chem. 276 (2001) 36530-36534
15. Blackwell K., Zhang L., Thomas G.S., Sun S., Nakano H., and Habelhah H. TRAF2 phosphorylation modulates TNFalpha-induced gene expression and cell resistance to apoptosis. Mol. Cell. Biol. 29 (2009) 303-314
16. Piao J.H., Yoshida H., Yeh W.C., Doi T., Xue X., Yagita H., et al. TNF receptor-associated factor 2-dependent canonical pathway is crucial for the development of Peyer's patches. J. Immunol. 178 (2007) 2272-2277
17. Sakon S., Xue X., Takekawa M., Sasazuki T., Okazaki T., Kojima Y., et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 22 (2003) 3898-3909
18. Ventura J.J., Kennedy N.J., Lamb J.A., Flavell R.A., and Davis R.J. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell. Biol. 23 (2003) 2871-2882
19. Okazaki T., Sakon S., Sasazuki T., Sakurai H., Doi T., Yagita H., et al. Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem. Biophys. Res. Commun. 300 (2003) 807-812
20. Zarnegar B., Yamazaki S., He J.Q., and Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc. Natl. Acad. Sci. USA 105 (2008) 3503-3508
21. Nakajima A., Komazawa-Sakon S., Takekawa M., Sasazuki T., Yeh W.C., Yagita H., et al. An antiapoptotic protein, c-FLIPL, directly binds to MKK7 and inhibits the JNK pathway. EMBO J. 25 (2006) 5549-5559
22. Hayden M.S., and Ghosh S. Shared principles in NF-kappaB signaling. Cell 132 (2008) 344-362
23. Shu H.B., Takeuchi M., and Goeddel D.V. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc. Natl. Acad. Sci. USA 93 (1996) 13973-13978
24. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
25. Lee T.H., Shank J., Cusson N., and Kelliher M.A. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J. Biol. Chem. 279 (2004) 33185-33191
26. Fotin-Mleczek M., Henkler F., Samel D., Reichwein M., Hausser A., Parmryd I., et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J. Cell Sci. 115 (2002) 2757-2770
27. Pobezinskaya Y.L., Kim Y.S., Choksi S., Morgan M.J., Li T., Liu C., and Liu Z. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat. Immunol. 9 (2008) 1047-1054
28. Ermolaeva M.A., Michallet M.C., Papadopoulou N., Utermohlen O., Kranidioti K., Kollias G., et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 9 (2008) 1037-1046
29. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30 (2008) 689-700
30. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (2007) 669-681
31. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007) 682-693
32. Wang L., Du F., and Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133 (2008) 693-703
33. Hoffmann A., Leung T.H., and Baltimore D. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. EMBO J. 22 (2003) 5530-5539
34. Hoffmann A., Levchenko A., Scott M.L., and Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298 (2002) 1241-1245
35. Budd R.C., Yeh W.C., and Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat. Rev. Immunol. 6 (2006) 196-204